Mumbai, August 4, 2026: Sanofi India Ltd. reported a strong operational performance for the quarter ended June 30, 2026 (Q2 2026), driven by robust growth in its diabetes portfolio and improved profitability. The company’s Board of Directors approved the unaudited financial results at its meeting held on August 4, 2026.
Sanofi India Q2 2026 Financial Highlights
- Total net sales increased 6% year-on-year.
- Domestic net sales grew 8% compared to Q2 2025.
- Profit before tax (before exceptional items) rose 19% to ₹112 crore, up from ₹94 crore in the corresponding quarter last year.
- PBT margin improved to 27%, compared with 24% in Q2 2025.
- Net profit stood at ₹83.5 crore, compared with ₹69.5 crore a year earlier.
The company attributed the improvement in profitability to a favorable product mix and disciplined cost management, with operating expenses declining 5% year-on-year.
Diabetes Business Continues Strong Momentum
Sanofi India’s diabetes portfolio remained the key growth driver during the quarter.
- The Insulin portfolio recorded 14% growth for the second consecutive quarter.
- The company maintained its leadership in the basal analog market with a 58% value market share and 61% volume market share.
- Growth was supported by brands including Lantus®, Toujeo®, Apidra®, and Soliqua®.
Sanofi also reported that its public sector business surged 70%, helped by new Toujeo® and Soliqua® accounts under the CARE Accounts initiative.
Strategic Partnerships Support Growth
The company said its strategic partnerships in the cardiovascular, oral anti-diabetes, and central nervous system segments continued to perform in line with expectations.
Partnership revenues increased 2% during the quarter, while export sales remained broadly stable despite global market headwinds.
Management Commentary
Managing Director Deepak Arora said the company delivered another quarter of profitable growth, supported by continued momentum in its diabetes business and disciplined execution.
He added that Sanofi India has built a strong foundation for long-term value creation through its expanding diabetes franchise, public sector presence, and modernized commercial model while continuing to focus on improving access to innovative therapies.
Board Approves Committee Changes
Apart from approving the quarterly financial results, the Board also approved the reconstitution of the Stakeholders Relationship Committee and the Risk Management Committee, effective October 1, 2026.
The company also approved the removal of Rachid Ayari from the list of Key Managerial Personnel authorized to determine materiality and make stock exchange disclosures following his decision to step down as Whole-Time Director and Chief Financial Officer effective September 30, 2026.
Key Financial Snapshot (Q2 2026)
- Revenue from Operations: ₹437.7 crore
- Total Income: ₹443.9 crore
- Profit Before Tax: ₹112.3 crore
- Net Profit: ₹83.5 crore
- Basic EPS: ₹36.26
Sanofi India stated that the financial results have been reviewed by the Audit Committee, approved by the Board of Directors, and subjected to a limited review by the statutory auditors.
Source: NSE Filing
